Skip to main content

Contineum Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

CTNM$9.52+8.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Page
PART I. · FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)1
Condensed Balance Sheets1
Condensed Statements of Operations and Comprehensive Income (Loss)2
Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)3
Condensed Statements of Cash Flows4
Notes to Unaudited Condensed Financial Statements5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations13
Item 3.Quantitative and Qualitative Disclosures About Market Risk20
Item 4.Controls and Procedures20
PART II.OTHER INFORMATION
Item 1.Legal Proceedings21
Item 1A.Risk Factors21
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds22
Item 3.Defaults Upon Senior Securities22
Item 4.Mine Safety Disclosures22
Item 5.Other Information22
Item 6.Exhibits23
Signatures25
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.